An observational study in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS), sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Charite University, Berlin, Germany.
Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, this one is one of 3 that started in 2013, is one of 5 observational ones, and was the 17th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 18–70
Charite University, Berlin, Germany · Sites in Germany
Ages 18–60 · Women only
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1
First in 2007; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 53 across the 14 interventional studies, 100 across the 5 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
1 of the studies in Multiple Sclerosis by Charite University, Berlin, Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07183683Charite University, Berlin, GermanyStimulation of Acupuncture Points in Female Patients With Multiple Sclerosis and Neurogenic Bladder Dysfunction | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Multiple Sclerosis by Charite University, Berlin, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life. In this prospective observational study, we obtain data on the outcome of pregnancies in MS patients and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.
Patients will be recruted at neurological outpatient clinics and neurological clinics of the Charité and neurologists' medical practices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with clinically isolated syndrome, relapsing-remitting or progressive multiple sclerosis
Time until relapse
Time (in days) until relapse during the observation period
Time frame: 12 months after delivery compared to baseline
Number of T2 lesions
Number of T2 lesions in spinal and cerebral magnetic resonance imaging
Time frame: 12 months after delivery compared to baseline
Number of gadolinium enhancing lesions
Number of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging
Time frame: 12 months after delivery compared to baseline
Volume of T2 lesions
Volume of T2 lesions in spinal and cerebral magnetic resonance imaging
Time frame: 12 months after delivery compared to baseline
Volume of gadolinium enhancing lesions
Volume of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging
Time frame: 12 months after delivery compared to baseline
Change in immune cell phenotypes
Change in immune cell phenotypes of peripheral blood mononuclear cells (PBMC)
Time frame: 12 months after delivery compared to baseline
Galectin-1
Change in serum galectin-1 concentration measured by ELISA
Time frame: 12 months after delivery compared to baseline
Galectin-3
Change in serum galectin-3 concentration measured by ELISA
Time frame: 12 months after delivery compared to baseline
Galectin-9
Change in serum galectin-9 concentration measured by ELISA
Time frame: 12 months after delivery compared to baseline
Neurofilament (NfL)
Change in neurofilament serum concentration by using Simoa NfL assay
Time frame: 12 months after delivery compared to baseline
Pro-inflammatory interleukin-17
Change in interleukin-17 serum concentration assessed by ELISA
Time frame: 12 months after delivery compared to baseline
Anti-inflammatory interleukin-10
Change in anti-inflammatory interleukin-10 serum concentration assessed by ELISA
Time frame: 12 months after delivery compared to baseline
Autoantibody profiling
Identification and quantification of autoantibodies by using protein microarray and ELISA
Time frame: 12 months after delivery compared to baseline
Fecal microbiome composition
Composition of fecal microbiome measured by 16S Sequencing
Time frame: 12 months after delivery compared to baseline
Thickness of the retinal nerve fibre layer
Thickness of the retinal nerve fibre layer by Optical Coherence Tomography (OCT)
Time frame: 12 months after delivery (compared to baseline)
Total macular volume (TMV)
Total macular volume by Optical Coherence Tomography (OCT)
Time frame: 12 months after delivery compared to baseline
Mini-International Neuropsychiatric Interview (M.I.N.I.) German Version 5.0.0 Module A-C
Structured diagnostic interview to assess depression, dysthymia and suicidality
Time frame: 12 months after delivery compared to baseline
Montgomery-Asberg Depression Rating Scale (MADRS)
Rating of ten depression related symptoms on a scale from 0 to 6 (higher numbers indicate more severe symptoms)
Time frame: 12 months after delivery compared to baseline
Beck Depression Inventory (BDI-II)
Rating of 21 depression related symptoms on a scale from 0 to 3 (higher numbers indicate more severe symptoms)
Time frame: 12 months after delivery compared to baseline
Edinburgh Postpartum Depression Scale (EPDS)
Self-report survey containing 10 items, each item is rated 0-3 (higher scores indicate a higher probability of postpartum depression)
Time frame: 12 months after delivery compared to baseline
Modified Fatigue Inventory Scale (MFIS)
Self-report survey containing 21 items, each item is rated 0-4 (higher scores indicate a greater impact of fatigue on a person's activities)
Time frame: 12 months after delivery compared to baseline
Fatigue Severity Scale (FSS)
A self-report survey consisting of 11 items, each item ranges from 1 to 7 (higher scores indicate higher levels of fatigue)
Time frame: 12 months after delivery compared to baseline
Visual Fatigue Analogue Scale (VFAS)
A self-administered, single scale indication measuring visual fatigue, ranging from 0 to 100 (higher scores indicate worse fatigue)
Time frame: 12 months after delivery compared to baseline
Short-Form Health Survey (SF-36)
A self-report survey measuring health in eight dimensions (higher scores indicate less disability)
Time frame: 12 months after delivery compared to baseline
Plan to share: Yes — Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification
Supporting information: Study protocol
Time frame: Beginning 9 months and ending 36 months following article publication
Access criteria: Researchers who provide a methodologically sound proposal
No publications or documents are linked to this record.
Started Jan 2013 (actual). Primary completion is estimated for Dec 2025, 155 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 155 months is above that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →